Takeda Pharmaceutical Company Limited - Asset Resilience Ratio
Takeda Pharmaceutical Company Limited (TKDA) has an Asset Resilience Ratio of 0.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Takeda Pharmaceutical Company Limited PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Takeda Pharmaceutical Company Limited's Asset Resilience Ratio has changed over time. See TKDA net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Takeda Pharmaceutical Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Takeda Pharmaceutical Company Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €107.00 Billion | 0.69% |
| Total Liquid Assets | €107.00 Billion | 0.69% |
Asset Resilience Insights
- Limited Liquidity: Takeda Pharmaceutical Company Limited maintains only 0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Takeda Pharmaceutical Company Limited Industry Peers by Asset Resilience Ratio
Compare Takeda Pharmaceutical Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 6.06% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 3.28% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
Annual Asset Resilience Ratio for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Takeda Pharmaceutical Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.14% | €20.48 Billion ≈ $23.94 Billion |
€14.25 Trillion ≈ $16.66 Trillion |
+0.04pp |
| 2024-03-31 | 0.10% | €15.09 Billion ≈ $17.64 Billion |
€15.11 Trillion ≈ $17.66 Trillion |
-0.04pp |
| 2023-03-31 | 0.14% | €20.17 Billion ≈ $23.59 Billion |
€13.96 Trillion ≈ $16.32 Trillion |
-0.05pp |
| 2022-03-31 | 0.19% | €25.30 Billion ≈ $29.58 Billion |
€13.18 Trillion ≈ $15.41 Trillion |
-0.09pp |
| 2021-03-31 | 0.28% | €36.60 Billion ≈ $42.79 Billion |
€12.91 Trillion ≈ $15.10 Trillion |
+0.16pp |
| 2020-03-31 | 0.12% | €15.82 Billion ≈ $18.50 Billion |
€12.82 Trillion ≈ $14.99 Trillion |
-0.04pp |
| 2019-03-31 | 0.17% | €23.28 Billion ≈ $27.21 Billion |
€13.87 Trillion ≈ $16.22 Trillion |
-1.80pp |
| 2018-03-31 | 1.96% | €80.65 Billion ≈ $94.28 Billion |
€4.11 Trillion ≈ $4.80 Trillion |
+0.66pp |
| 2017-03-31 | 1.30% | €56.68 Billion ≈ $66.27 Billion |
€4.36 Trillion ≈ $5.09 Trillion |
-- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more